; The Radiation Research and Translational Biology, (RRTB) program goal is to improve combination radiation therapies by 1) designing and testing new molecular targets identified by mechanistic studies, and 2) addressing tumor resistance to therapy and bypass of immune surveillance, and 3) designing, assessing and improving technologies that diagnose, stage, and deliver therapies for cancer patients. Program members address these goals with multidisciplinary efforts in biochemistry, immunology, drug design, preclinical models, and clinical experience, to accelerate translation from bench to bedside. The Program has been strengthened by integration of members from the former Program in Cancer Immunology. The current RRTB program, comprised of 34 basic, translational and clinical investigators from eleven departments, thus combines basic and clinical research strengths to conduct bench to bedside research and can reverse translate clinical data to inform further translational innovations. This work is supported by 36 peer-reviewed grants totaling direct funds of $13.2 million ($5.3 million from NCI). The total number of publications generated by Program members from 2007 to 2012 is 543 of which 11% are Intra-programmmatic and 22% are Inter-programmatic, with 4.6% being both. The specific research themes ofthe RRTB Program are: (1) Improve RT therapies by defining and characterizing molecular targets for ionizing radiation and for combined therapies, vaccine development and BMT (2) Immune tolerance and strategies for immune surveillance. (3) Tumor resistance: Microenvironment, hypoxia and angiogenesis. (4) Protecting normal tissues: normal tissue injury/genotoxic stress. (5) Clinical translation of diagnostic and therapeutic innovations, and (6) Improving clinical practice: Biomedical/Bioinformatics and Comparitive Effectiveness Research (CER). This program will continually generate new collaborations, intra- and interprogrammatically, and fresh research directions with other research programs in the cancer center.
; The Radiation Research and Translational Biology (RRTB) program is improving cancer treatment by increasing the killing of cancer cells while protecting normal tissues. Its basic and clinical researchers combine innovations in radiation technology and imaging techniques with drugs targeting tumor cells (or the surrounding tissues) to help physicians make better diagnoses and choose the best course of therapy.
|Li, Jifen; Gao, Erhe; Vite, Alexia et al. (2015) Alpha-catenins control cardiomyocyte proliferation by regulating Yap activity. Circ Res 116:70-9|
|Basile, Kevin J; Le, Kaitlyn; Hartsough, Edward J et al. (2014) Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors. Pigment Cell Melanoma Res 27:479-84|
|Sonar, Mahesh V; Wampole, Matthew E; Jin, Yuan-Yuan et al. (2014) Fluorescence detection of KRAS2 mRNA hybridization in lung cancer cells with PNA-peptides containing an internal thiazole orange. Bioconjug Chem 25:1697-708|
|Gu, Lei; Talati, Pooja; Vogiatzi, Paraskevi et al. (2014) Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther 13:1246-58|
|Bhardwaj, Anshul; Casjens, Sherwood R; Cingolani, Gino (2014) Exploring the atomic structure and conformational flexibility of a 320?Å long engineered viral fiber using X-ray crystallography. Acta Crystallogr D Biol Crystallogr 70:342-53|
|Siciliano, Nicholas A; Hersperger, Adam R; Lacuanan, Aimee M et al. (2014) Impact of distinct poxvirus infections on the specificities and functionalities of CD4+ T cell responses. J Virol 88:10078-91|
|Clark, Peter M; Loher, Phillipe; Quann, Kevin et al. (2014) Argonaute CLIP-Seq reveals miRNA targetome diversity across tissue types. Sci Rep 4:5947|
|Li, Yuan; Liang, Chunli; Ma, Haizhong et al. (2014) miR-221/222 promotes S-phase entry and cellular migration in control of basal-like breast cancer. Molecules 19:7122-37|
|Wilson, Chantell; Lin, Jieru E; Li, Peng et al. (2014) The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. Cancer Epidemiol Biomarkers Prev 23:2328-37|
|Khasnis, Mukta; Nakatomi, Akiko; Gumpper, Kristyn et al. (2014) Reconstituted human myosin light chain phosphatase reveals distinct roles of two inhibitory phosphorylation sites of the regulatory subunit, MYPT1. Biochemistry 53:2701-9|
Showing the most recent 10 out of 343 publications